poisar

Stocks · News reference

OKYO Pharma Announces First Patients Enrolled In Phase 3 NEPTUNE Trial Of Urcosimod For Neuropathic Corneal Pain

Benzinga Newsdesk

NEPTUNE is evaluating urcosimod as a potential first-in-class treatment for neuropathic corneal painFirst patients enrolled by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN LONDON and NEW YORK, Oct. 06, 2026 (GLOBE

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

OKYO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading